The safety picture for injected NAD+ comes from small pilot studies and anecdotal reports, not large trials. During faster IV infusion, commonly reported effects include flushing, nausea, abdominal cramping, increased heart rate, and chest pressure, which tend to resolve once the infusion ends.[1][2]
Reviewed for accuracy · Last reviewed July 8, 2026In one slow 6-hour infusion pilot no adverse events were reported, which suggests the rate of infusion matters. In a small retrospective real-world series, all participants in the NAD+ group reported moderate to severe infusion-related symptoms, and infusions were slowed to manage them. Both datasets are small, so this should be read as preliminary rather than a full safety profile.
Because injected NAD+ is not an FDA-approved therapy and lacks large trials, its longer-term safety is not well characterized. The better-characterized human safety data concern oral precursors (NR, NMN), which is a different route and should not be assumed to apply to injection.
Slower infusion rates are the most commonly described way to limit flushing, nausea, and chest pressure. Any concerning symptom, especially chest pain that does not resolve, warrants stopping and seeking medical advice.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.